Judith E. Karp

Sheba Medical Center — Israel

Medicine · Health Sciences

78h-index19.2kcitations484works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(232), Acute Lymphoblastic Leukemia research(75), Chronic Myeloid Leukemia Treatments(59), Chronic Lymphocytic Leukemia Research(56), Histone Deacetylase Inhibitors Research(41)

Publications474 total

P18.18.B A NOVEL, POOLED, HIGH-THROUGHPUT SCREENING OF A CNS PENETRANT COMPOUND LIBRARY IDENTIFIES POTENTIAL BIOMARKER-DRIVEN THERAPEUTICS FOR GLIOBLASTOMA
Neuro-Oncology·2025Open Access
Genomic testing and patient rights
JNCI Journal of the National Cancer Institute·2024· 1 citedOpen Access
Improving Transparency in Phase 1 Clinical Trials
2024
Pyrimidine- and Purine-Based Antimetabolites, Hydroxyurea, and Asparaginases
2023
Cancer Pharmacology
2023· 1 cited
Third-Party Cytotoxic T Lymphocytes for High-Risk Patients with Covid-19
immuneACCESS·2023
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
Leukemia·2023· 14 citedOpen Access
Systematic review and meta‐analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia
Cancer·2023· 14 citedOpen Access
Supplemental Figure 1 from Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
2023Open Access
Data from A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
2023Open Access
Supplemental Figures and Tables from A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
2023Open Access
Supplemental Data from Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
2023Open Access
Data from Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells <i>In Vitro</i>
2023Open Access
Data from Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells <i>In Vitro</i>
2023Open Access
Data from A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
2023Open Access
Supplemental Figure 3B from Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
2023Open Access
Supplementary Figures S1-S2 from NF1 Inactivation in Adult Acute Myelogenous Leukemia
2023Open Access
Supplementary Tables 1 - 2, Figure 1 from Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells <i>In Vitro</i>
2023Open Access
Supplemental Table and Figures from Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
2023Open Access
Supplemental Figure 2 from Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
2023Open Access
page 1 of 24Next →

Frequent Co-authors

Scott H. Kaufmann(9), Philip J. Burke(8), William G. Merz(7), Rein Saral(7), Ivana Gojo(6), Mark J. Levis(6), Steven D. Gore(5), Jeffrey E. Lancet(5), B. Douglas Smith(5), James R. Wright(4), Jacqueline M. Greer(4), John R. Wingard(3), Michael A. McDevitt(3), James A. Zwiebel(3), Patrick A. Burch(3), Keith W. Pratz(3), Lawrence E. Morris(3), Michael G. Rinaldi(2), Stephen B. Baylin(2), Hetty E. Carraway(2)